Macrophages, inflammation, and atherosclerosis

International Journal of Obesity

Volumn 27, Issue SUPPL. 3, 2003, Pages

  Linton, MacRae F ^a,b   Fazio, Sergio ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACAT; aP2; apoE; Atherosclerosis; COX; Cytokine; Macrophage; Monocytes

Indexed keywords

APOLIPOPROTEIN E; CD36 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHOLESTEROL ESTER; CYCLOOXYGENASE 2; FATTY ACID BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN AP2; UNCLASSIFIED DRUG;

ADIPOCYTE; ARTERY INTIMA; ATHEROGENESIS; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; CYTOKINE PRODUCTION; ESTERIFICATION; FOAM CELL; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MACROPHAGE; MEDIATOR; MOLECULAR MECHANICS; MONOCYTE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REGULATORY MECHANISM;

ANIMALS; ARTERIOSCLEROSIS; CARRIER PROTEINS; CYCLOOXYGENASE 2; FATTY ACID-BINDING PROTEINS; HUMANS; INFLAMMATION; ISOENZYMES; MACROPHAGES; MEMBRANE PROTEINS; MICE; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TUMOR SUPPRESSOR PROTEINS;

EID: 0347511008     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802498     Document Type: Conference Paper

References (39)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Fazio S, Linton MF. Mouse models of hyperlipidemia and atherosclerosis. Front Biosci 2001; 6: D515-D525.
3. Peters W, Charo IF. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr Opin Lipidol 2001; 12: 175-180.
4. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998; 101: 353-363.
5. Huo Y, Weber C, Forlow SB, Sperandio M, Thatte J, Mack M, Jung S, Littman DR, Ley K. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest 2001; 108: 1307-1314.
6. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890.
7. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decrease atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995; 92: 8264-8268.
8. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931-1936.
9. Lee TS, Yen HC, Pan CC, Chau LY. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 734-742.
10. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99: 2752-2761.
11. Panousis CG, Zuckerman SH. Interferon-gamma induces downregulation of Tangier disease gene (ATP-binding-cassette transporter 1) in macrophage-derived foam cells. Arterioscler Thromb Vasc Biol 2000; 20: 1565-1571.
12. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H, Curtiss LK, Berliner JA, Boisvert WA. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002; 90: 1064-1071.
13. Linton MF, Fazio S. Cyclooxygenase-2 and atherosclerosis. Curr Opin Lipidol 2002; 13: 497-504.
14. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002; 105: 1816-1823.
15. Eligini S, Brambilla M, Banfi C, Camera M, Sironi L, Barbieri SS, Auwerx J, Tremoli E, Colli S. Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-kappaB/IkappaB- and ERK2-dependent mechanisms. Cardiovasc Res 2002; 55: 406-415.
16. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 2001; 98: 3358-3363.
17. Krul ES, Napawan N, Butteiger DT, Hayes K, Krause L, Freidrich GE, Broschat KO, Keller BT. Atherosclerosis is reduced in cholesterol-fed apoE(-/-) mice administered an ASBT inhibitor or a selective COX-2 inhibitor. Arterioscler Thromb Vasc Biol 2002; 22: P409 (online).
18. Santamarina-Fojo S, Remaley AT, Neufeld EB, Brewer HB, Jr. Regulation and intracellular trafficking of the ABCA1 transporter. J Lipid Res 2001; 42: 1339-1345.
19. Aiello RJ, Brees D, Bourassa PA, Royer L, Lindsey S, Coskran T, Haghpassand M, Francone OL. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 2002; 22: 630-637.
20. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apoE deficient mice by bone marrow transplantation. Science 1995; 267: 1034-1037.
21. Fazio S, Babaev VR, Murray AB, Hasty AH, Carter KJ, Gleaves LA, Atkinson JB, Linton MF. Increased atherosclerosis in C57BL/6 mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci USA 1997; 94: 4647-4652.
22. Ishiguro H, Yoshida H, Major AS, Zhu T, Babaev VR, Linton MF, Fazio S. Retrovirus-mediated expression of apolipoprotein A-I in the macrophage protects against atherosclerosis in vivo. J Biol Chem 2001; 276: 36742-36748.
23. Major AS, Dove DE, Ishiguro H, Su YR, Brown AM, Liu L, Carter KJ, Linton MF, Fazio S. Increased cholesterol efflux in apolipoprotein AI (ApoAI) -producing macrophages as a mechanism for reduced atherosclerosis in ApoAI(-/-) mice. Arterioscler Thromb Vasc Biol 2001; 21: 1790-1795.
24. Hasty AH, Linton MF, Brandt SJ, Babaev VR, Gleaves LA, Fazio S. Retroviral gene therapy in ApoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation. Circulation 1999; 99: 2571-2576.
25. Yoshida H, Hasty AH, Major AS, Ishiguro H, Su YR, Gleaves LA, Babaev VR, Linton MF, Fazio S. Isoform-specific effects of apolipoprotein E on atherogenesis: gene transduction studies in mice. Circulation 2001; 104: 2820-2825.
26. Fazio S, Babaev VR, Burleigh ME, Major AS, Hasty AH, Linton MF. Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice. J Lipid Res 2002; 43: 1602-1609.
27. Mazzone T, Gump H, Diller P, Getz G. Macrophage free cholesterol content regulates apolipoprotein E synthesis. J Biol Chem 1987; 262: 11657-11662.
28. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 2001; 98: 507-512.
29. Huang ZH, Lin CY, Oram JF, Mazzone T. Sterol efflux mediated by endogenous macrophage ApoE expression is independent of ABCA1. Arterioscler Thromb Vasc Biol 2001; 21: 2019-2025.
30. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer Jr HB, Gonzalez FJ. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 2002; 22: 2607-2619.
31. Werb Z, Chin JR. Apoprotein E is synthesized and secreted by resident and thioglycollate-elicited macrophages but not by pyran copolymer-or bacillus Calmette-Guerin-activated macrophages. J Exp Med 1983; 158: 1272-1293.
32. Fazio S, Major AS, Swift LL, Gleaves LA, Accad M, Linton MF, Farese Jr RV. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest 2001; 107: 163-171.
33. Feng B, Tabas I. ABCA1-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages. J Biol Chem 2002; 277: 43271-43280.
34. Boord JB, Fazio S, Linton MF. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol 2002; 13: 141-147.
35. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274: 1377-1379.
36. Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 2000; 141: 3388-3396.
37. Coe NR, Simpson MA, Bernlohr DA. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res 1999; 40: 967-972.
38. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001; 7: 699-705.
39. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002; 22: 1686-1691.